Treatment with the TGFβ receptor inhibitor galunisertib significantly restores CD8+ T cell infiltration and activates Th1 immune responses, thereby inhibiting primary tumor growth and liver metastasis formation (71). This evidence concerns the gene CD8A and neoplasm.